On June 22, RemeGen (09995.HK) fell 5.33% in regular trading, trading at HKD 64.35 per share, with turnover of HKD 112 million.

On the news front, the Hong Kong-listed innovative drug sector has been under sustained selling pressure since early June, with an accelerating downtrend. On the same day, the broader biotechnology sector saw widespread declines, with AKESO down 7.25%, SKB Bio down 6.45%, 3SBio down 4.37%, Innovent Bio down 4.33%, and BeiGene down 3.42%, reflecting deeply depressed sector sentiment.

Market concerns have intensified over rising expectations for a Fed rate hike and uncertainties surrounding BD (business development) overseas licensing prospects. Combined with profit-taking pressure following significant cumulative gains in the prior period, capital outflows from the innovative drug sector have persisted. The sector-wide selloff reflects macro and industry-level headwinds rather than company-specific catalysts, as multiple leading biotech names experienced comparable declines.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)